Trastuzumab-deruxtecan: redefining HER2 as a tumor agnostic biomarker
J Zouein, E Karam, JH Strickler, HR Kourie - Targeted Oncology, 2024 - Springer
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) targeting HER2-
positive malignancies across various tumor types. Through its unique composition, T-DXd …
positive malignancies across various tumor types. Through its unique composition, T-DXd …
Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies
NS Kiran, C Yashaswini, R Maheshwari… - ACS Pharmacology & …, 2024 - ACS Publications
Precision medicine is transforming colorectal cancer treatment through the integration of
advanced technologies and biomarkers, enhancing personalized and effective disease …
advanced technologies and biomarkers, enhancing personalized and effective disease …
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
H Singh, P Sahgal, K Kapner, SM Corsello… - Clinical Cancer …, 2024 - AACR
Purpose: ERBB2-amplified colorectal cancer is a distinct molecular subtype with expanding
treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known …
treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known …
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
M Tufail, WD Wan, C Jiang, N Li - Chemico-Biological Interactions, 2024 - Elsevier
This review comprehensively explores the challenge of drug resistance in cancer by
focusing on the pivotal PI3K/AKT/mTOR pathway, elucidating its role in oncogenesis and …
focusing on the pivotal PI3K/AKT/mTOR pathway, elucidating its role in oncogenesis and …
Hallmarks of cancer resistance
M Tufail, JJ Hu, J Liang, CY He, WD Wan, YQ Huang… - Iscience, 2024 - cell.com
This review explores the hallmarks of cancer resistance, including drug efflux mediated by
ATP-binding cassette (ABC) transporters, metabolic reprogramming characterized by the …
ATP-binding cassette (ABC) transporters, metabolic reprogramming characterized by the …
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A …
KPS Raghav, KA Guthrie, B Tan Jr… - Journal of Clinical …, 2025 - ascopubs.org
PURPOSE ERBB2 overexpression/amplification in RAS/BRAF wild-type (WT) metastatic
colorectal cancer (mCRC; human epidermal growth factor receptor 2 [HER2]-positive …
colorectal cancer (mCRC; human epidermal growth factor receptor 2 [HER2]-positive …
Personalised medicine based on host genetics and microbiota applied to colorectal cancer
A González, I Badiola, A Fullaondo… - Advances in …, 2024 - pubmed.ncbi.nlm.nih.gov
Colorectal cancer (CRC) ranks second in incidence and third in cancer mortality worldwide.
This situation, together with the understanding of the heterogeneity of the disease, has …
This situation, together with the understanding of the heterogeneity of the disease, has …